

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
28 April 2005 (28.04.2005)

PCT

(10) International Publication Number
WO 2005/037995 A2

(51) International Patent Classification⁷: C12N

(21) International Application Number:
PCT/US2004/032669

(22) International Filing Date: 5 October 2004 (05.10.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/508,945 6 October 2003 (06.10.2003) US

(71) Applicant (for all designated States except US):
CEDARS-SINAI MEDICAL CENTER [US/US];
8700 Beverly Boulevard, Los Angeles, CA 90048-1865
(US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **YU, John, S.**
[US/US]; 269 Ashdale Place, Los Angeles, CA 90048
(US). **AKASAKI, Yasuharu** [JP/JP]; 10811 Ashton
Avenue, #104, Los Angeles, CA 90024 (US).

(74) Agents: **LEVY, Seth, D.** et al.; Davis Wright Tremaine
LLP, 865 Figueroa Street, Suite 2400, Los Angeles, CA
90017-2566 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).


Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: USE OF COX-2 INHIBITOR TO PREVENT T-CELL ANERGY INDUCED BY DENDRITIC CELL THERAPY

(57) Abstract: The present invention relates to a method and combination therapy useful in the treatment of cancer. More specifi-
cally, the invention relates to the use of COX-2 inhibitors in combination with a therapeutic dendritic cell vaccine for treating cancer.
The COX-2 inhibitors of the present invention are believed to inhibit the enzymatic activity of prostaglandinE₂ (PGE₂); thereby
preventing COX-2 overexpressing tumors from evading immune surveillance by antigen-specific cytotoxic T lymphocytes (CTLs).
COX-2 inhibitors are believed to suppress PGE₂ that COX-2 overexpressing glioma produce, allowing tumor-infiltrating DCs to
polarize Th cells toward Th-subset-1 (Th1).



WO 2005/037995 A2